2013年3月5日訊 /生物谷BIOON/ --武田（Takeda）與美國生物技術公司Resolve Therapeutics達成了合作夥伴關係，共同開發化合物，用於治療紅斑狼瘡及其他自身免疫性疾病。先導化合物RSLV-132是一種核酶Fc融合蛋白，能夠降解並清除含有自身抗體的免疫複合物。雙方將在今年晚些時期啟動該化合物的臨床開發。此外，還有數種化合物處於臨床前的概念驗證階段。（生物谷bioon.com）
詳細英文報導：
The lead compound, RSLV-132, is a nuclease Fc fusion protein that degrades and eliminates autoantibody-containing immune complexes, which are thought to be the most proximal pathophysiological trigger of lupus. It will begin clinical development later this year. Additional Resolve clinical candidates are in the pre-clinical proof-of-concept stage.
Resolve will conduct all development work under the collaboration until completion of the first RSLV-132 Phase 1b/2a trial in lupus patients. Takeda has the exclusive option to license the lead compound and all other compounds from the Resolve platform upon the completion of the Phase 1b/2a trial. Upon exercise of its option, Takeda would assume lead responsibility for worldwide development and commercialization of the Resolve products.
Under the terms of the agreement, Takeda will help fund continued development of RSLV-132 through an initial payment of US$8 million to Resolve in fiscal 2012. Upon exercise of its option, Takeda would pay Resolve an option exercise fee, plus the potential for additional development milestones totaling US$247 million. Furthermore Resolve is eligible to receive royalties on product sales.